open access
Ranibizumab in Diabetic Macular Edema; Level 1 and Level 2 Studies Findings
Affiliations- Universitas Padjadjaran, Jl. Cicendo No 4, 40171 Bandung, Indonesia
- Universitas Indonesia, Indonesia
- Universitas Hasanudin, Indonesia
open access
Abstract
INTRODUCTION. Ranibizumab is an anti-VEGF antibody widely used in DME treatment.
MATERIALS AND METHODS. We conducted a literature search using the keywords “diabetes”, “diabetic retinopathy”, “diabetic macular edema”, “pathophysiology”, “VEGF”, “treatment”, “anti-VEGF”, “ranibizumab”, “lucentis” with limitation of English language. The articles published between 2006–2016 years and we reviewed level I and level II studies.
RESULTS. Review from several level I and level II intravitreal ranibizumab injection studies suggests that ranibizumab is an anti-VEGF that effectively used in DME treatment. Comparison with other anti-VEGF also suggest that ranibizumab is effective for DME patients for over 2 years treatment.
CONCLUSIONS. Ranibizumab monotherapy and/or combination with laser is safe and effective for DME patients for over 2 years treatment.
Abstract
INTRODUCTION. Ranibizumab is an anti-VEGF antibody widely used in DME treatment.
MATERIALS AND METHODS. We conducted a literature search using the keywords “diabetes”, “diabetic retinopathy”, “diabetic macular edema”, “pathophysiology”, “VEGF”, “treatment”, “anti-VEGF”, “ranibizumab”, “lucentis” with limitation of English language. The articles published between 2006–2016 years and we reviewed level I and level II studies.
RESULTS. Review from several level I and level II intravitreal ranibizumab injection studies suggests that ranibizumab is an anti-VEGF that effectively used in DME treatment. Comparison with other anti-VEGF also suggest that ranibizumab is effective for DME patients for over 2 years treatment.
CONCLUSIONS. Ranibizumab monotherapy and/or combination with laser is safe and effective for DME patients for over 2 years treatment.
Keywords
diabetic macular edema, anti VEGF, ranibizumab
About this articleTitle
Ranibizumab in Diabetic Macular Edema; Level 1 and Level 2 Studies Findings
Journal
Issue
Article type
Review paper
Pages
14-20
Published online
2018-07-20
Page views
547
Article views/downloads
684
DOI
Bibliographic record
Ophthalmol J 2018;3(1):14-20.
Keywords
diabetic macular edema
anti VEGF
ranibizumab
Authors
Arief Kartasasmita
Elvis Elvioza
Habibah S Muhiddin
References (25)- Cho NH, et al. IDF Diabetes Atlas, International Diabetes Federation (IDF), Brussels, Belgium, 7th edition. 2015.
- American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2014; 37(suppl1): 81–90.
- Cheung N, et al. et al.. Diabetic Retinopathy Lancet. 2010; 376: 124–36.
- Diabetic Retinopathy Preferred Practice Pattern® (“PPP”) guidelines. Updated 2016. https://www.aao.org/preferred-practice-pattern/diabetic-retinopathy-ppp-updated-2016. (Accessed on 14th Aug).
- Yau JWY, Rogers SL, Kawasaki R, et al. Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012; 35(3): 556–564.
- Lang GE. Diabetic macular edema. Ophthalmologica. 2012; 227 Suppl 1: 21–29.
- Scholl S, Augustin A, Loewenstein A, et al. Pathophysiology of macular edema. Ophthalmologica. 2010; 224 Suppl 1: 8–15.
- Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol. 2006; 142(6): 961–969.
- https://www.elsevier.com/__data/promis_misc/623124los.pdf. (Accessed on 28 Aug 2017).
- Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006; 26(8): 859–870.
- Chun DW, Heier JS, Topping TM, et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology. 2006; 113(10): 1706–1712.
- EDWARDS P. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Acta Ophthalmologica. 2010; 88: 0–0.
- Elman MJ, Bressler NM, Qin H, et al. Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011; 118(4): 609–614.
- Sivaprasad S, Regnier SA, Fajnkuchen F, et al. RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011; 118(4): 615–625.
- Nguyen QD, Brown DM, Marcus DM, et al. RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012; 119(4): 789–801.
- Wells JA, Glassman AR, Ayala AR, et al. Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015; 372(13): 1193–1203.
- Wells J, Glassman A, Ayala A, et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. Ophthalmology. 2016; 123(6): 1351–1359.
- Elman MJ, Qin H, Aiello LP, et al. Diabetic Retinopathy Clinical Research Network. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology. 2012; 119(11): 2312–2318.
- Elman MJ, Ayala A, Bressler NM, et al. Diabetic Retinopathy Clinical Research Network. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015; 122(2): 375–381.
- Lang GE, Berta A, Eldem BM, et al. RESTORE Extension Study Group. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology. 2013; 120(10): 2004–2012.
- Schmidt-Erfurth U, Lang GE, Holz FG, et al. RESTORE Extension Study Group. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology. 2014; 121(5): 1045–1053.
- Brown D, Nguyen Q, Marcus D, et al. Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials. Ophthalmology. 2013; 120(10): 2013–2022.
- Massin P, et al. Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study). Diabetes Care. 2010; 33: 2399–2405.
- Nguyen QD, Shah SM, Heier JS, et al. READ-2 Study Group. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2009; 116(11): 2175–21781.e1.
- Nguyen QD, Shah SM, Khwaja AA, et al. READ-2 Study Group. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010; 117(11): 2146–2151.